Bartlett & CO. Wealth Management LLC Reduces Position in Becton, Dickinson and Company $BDX

Bartlett & CO. Wealth Management LLC decreased its holdings in Becton, Dickinson and Company (NYSE:BDX) by 30.6% in the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 19,305 shares of the medical instruments supplier’s stock after selling 8,514 shares during the quarter. Bartlett & CO. Wealth Management LLC’s holdings in Becton, Dickinson and Company were worth $2,825,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of BDX. Brighton Jones LLC grew its stake in shares of Becton, Dickinson and Company by 98.2% in the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock worth $401,000 after acquiring an additional 877 shares during the period. Empowered Funds LLC lifted its position in Becton, Dickinson and Company by 20.4% during the first quarter. Empowered Funds LLC now owns 7,977 shares of the medical instruments supplier’s stock valued at $1,827,000 after purchasing an additional 1,354 shares during the period. United Bank boosted its holdings in Becton, Dickinson and Company by 23.9% in the second quarter. United Bank now owns 5,149 shares of the medical instruments supplier’s stock worth $887,000 after purchasing an additional 993 shares during the last quarter. Marshall Wace LLP grew its position in Becton, Dickinson and Company by 365.1% in the 2nd quarter. Marshall Wace LLP now owns 31,876 shares of the medical instruments supplier’s stock worth $5,491,000 after purchasing an additional 25,022 shares during the period. Finally, NewEdge Advisors LLC grew its position in Becton, Dickinson and Company by 34.7% in the 2nd quarter. NewEdge Advisors LLC now owns 23,501 shares of the medical instruments supplier’s stock worth $4,048,000 after purchasing an additional 6,058 shares during the period. Institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Trading Down 1.1%

Shares of Becton, Dickinson and Company stock opened at $158.14 on Friday. Becton, Dickinson and Company has a 1-year low of $127.59 and a 1-year high of $187.35. The company’s fifty day simple moving average is $148.99 and its 200-day simple moving average is $166.39. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.94 and a quick ratio of 0.55. The stock has a market capitalization of $43.57 billion, a PE ratio of 40.04, a P/E/G ratio of 11.19 and a beta of 0.21.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings data on Thursday, May 7th. The medical instruments supplier reported $2.90 EPS for the quarter, topping the consensus estimate of $2.77 by $0.13. Becton, Dickinson and Company had a return on equity of 15.37% and a net margin of 5.33%.The firm had revenue of $4.71 billion during the quarter, compared to analyst estimates of $4.67 billion. During the same period in the prior year, the business posted $3.35 EPS. Becton, Dickinson and Company’s revenue was up 5.2% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. As a group, equities analysts anticipate that Becton, Dickinson and Company will post 12.62 earnings per share for the current year.

Becton, Dickinson and Company Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Tuesday, June 30th. Shareholders of record on Tuesday, June 9th were given a $1.05 dividend. The ex-dividend date was Tuesday, June 9th. This represents a $4.20 dividend on an annualized basis and a yield of 2.7%. Becton, Dickinson and Company’s dividend payout ratio is presently 106.33%.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the company. Zacks Research raised Becton, Dickinson and Company from a “strong sell” rating to a “hold” rating in a report on Friday, April 10th. Wells Fargo & Company lifted their price objective on Becton, Dickinson and Company from $157.00 to $161.00 and gave the stock an “equal weight” rating in a report on Friday, May 8th. Weiss Ratings cut Becton, Dickinson and Company from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Monday, May 11th. Royal Bank Of Canada set a $175.00 target price on Becton, Dickinson and Company in a research report on Tuesday, April 14th. Finally, Barclays boosted their price target on Becton, Dickinson and Company from $202.00 to $204.00 and gave the company an “overweight” rating in a research note on Monday, May 11th. Seven research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $180.29.

Insider Activity

In other news, EVP Michael David Garrison sold 1,100 shares of the firm’s stock in a transaction dated Wednesday, June 24th. The stock was sold at an average price of $145.66, for a total value of $160,226.00. Following the transaction, the executive vice president owned 13,172 shares of the company’s stock, valued at $1,918,633.52. This trade represents a 7.71% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Thomas E. Polen, Jr. sold 2,764 shares of Becton, Dickinson and Company stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $146.35, for a total value of $404,511.40. Following the transaction, the chief executive officer directly owned 110,163 shares in the company, valued at approximately $16,122,355.05. The trade was a 2.45% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 5,188 shares of company stock worth $765,120 in the last ninety days. Corporate insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.